The effect of intravenous peramivir, compared with oral oseltamivir, on the outcome of post-influenza pneumococcal pneumonia in mice

Antiviral Therapy

Volumn 20, Issue 1, 2015, Pages 11-19

  Tanaka, Akitaka ^a   Nakamura, Shigeki ^a   Seki, Masafumi ^b   Iwanaga, Naoki ^a   Kajihara, Toshiki ^a   Kitano, Mitsutaka ^c   Homma, Tomoyuki ^c   Kurihara, Shintaro ^a   Imamura, Yoshifumi ^a   Miyazaki, Taiga ^a   Izumikawa, Koichi ^a   Kakeya, Hiroshi ^a   Yanagihara, Katsunori ^a   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY HOSPITAL   (Japan)

^c SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL1 CHEMOKINE; CXCL3 CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 6; OSELTAMIVIR; PERAMIVIR; TUMOR NECROSIS FACTOR ALPHA; ANTIVIRUS AGENT; CHEMOKINE; CXCL2 CHEMOKINE; CXCL2 PROTEIN, MOUSE; CYCLOPENTANE DERIVATIVE; GUANIDINE DERIVATIVE; KERATINOCYTE DERIVED CHEMOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BACTERIAL LOAD; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; INFECTION SENSITIVITY; INFLUENZA; MALE; MIXED INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; VIRUS TITRATION; ANIMAL; BIOSYNTHESIS; CBA MOUSE; DRUG EFFECTS; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INTRAVENOUS DRUG ADMINISTRATION; LUNG; MICROBIOLOGY; MORTALITY; ORAL DRUG ADMINISTRATION; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL; VIROLOGY;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; CHEMOKINE CXCL2; CHEMOKINES; COINFECTION; CYCLOPENTANES; GUANIDINES; INFLUENZA A VIRUS, H1N1 SUBTYPE; INTERFERON-GAMMA; INTERLEUKIN-6; LUNG; MALE; MICE; MICE, INBRED CBA; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84927712976     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2744     Document Type: Article

References (47)

1. Hoyert DL, Xu J. Deaths: preliminary data for 2011. Natl Vital Stat Rep 2012; 61:1-51.
2. Hsu J, Santesso N, Mustafa R, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med 2012; 156:512-524.
3. Chemaly RF, Torres HA, Aguilera EA, et al. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clin Infect Dis 2007; 44:964-967.
4. Hernán MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis 2011; 53:277-279.
5. Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic; a systematic review and meta-analysis in hospitalized patients. J Infect Dis 2013; 207:553-563.
6. Yang SG, Cao B, Liang LR, et al. Antiviral therapy and outcomes of patients with pneumonia caused by influenza A pandemic (H1N1) virus. PLoS ONE 2012; 7:e29652.
7. Louie JK, Yang S, Acosta M, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A(H1N1)pdm09. Clin Infect Dis 2012; 55:1198-1204.
8. Yu H, Liao Q, Yuan Y, et al. Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China. BMJ 2010; 341:c4779.
9. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1003-1032.
10. Bantia S, Kellogg D, Parker C, Upshaw R, Ilyushina NA, Babu YS. A single intramuscular injection of neuraminidase inhibitor peramivir demonstrates antiviral activity against novel pandemic A/California/04/2009 (H1N1) influenza virus infection in mice. Antiviral Res 2011; 90:17-21.
11. Yun NE, Linde NS, Zacks MA, et al. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/ Vietnam/1203/04 (H5N1). Virology 2008; 374:198-209.
12. Centers for Disease Control and Prevention. Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep 2009; 58:433-435.
13. Birnkrant D, Cox E. The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 2009; 361:2204-2207.
14. Hernandez JE, Adiga R, Armstrong R, et al. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States. Clin Infect Dis 2011; 52:695-706.
15. Kohno S, Kida H, Mizuguchi M, et al. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob Agents Chemother 2011; 55:2803-2812.
16. Kohno S, Kida H, Mizuguchi M, Shimada J. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother 2010; 54:4568-4574.
17. Kohno S, Yen MY, Cheong HJ, et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother 2011; 55:5267-5276.
18. Sorbello A, Jones SC, Carter W, et al. Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus. Clin Infect Dis 2012; 55:1-7.
19. LeVine AM, Koeningsknecht V, Stark JM. Decreased pulmonary clearance of S. pneumoniae following influenza A infection in mice. J Virol Methods 2001; 94:173-186.
20. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 2006; 19:571-582.
21. Broug-Holub E, Toews GB, van Iwaarden J F, et al. Alveolar macrophages are required for protective pulmonary defenses in murine Klebsiella pneumonia: elimination of alveolar macrophages increases neutrophil recruitment but decreases bacterial clearance and survival. Infect Immun 1997; 65:1139-1146.
22. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008; 198:962-970.
23. Pittet LA, Hall-Stoodley L, Rutkowski MR, Harmsen AG. Influenza virus infection decreases tracheal mucociliary velocity and clearance of Streptococcus pneumoniae. Am J Respir Cell Mol Biol 2010; 42:450-460.
24. Peltola VT, Murti KG, McCullers JA. Influenza virus neuraminidase contributes to secondary bacterial pneumonia. J Infect Dis 2005; 192:249-257.
25. Colamussi ML, White MR, Crouch E, Hartshorn KL. Influenza A virus accelerates neutrophil apoptosis and markedly potentiates apoptotic effects of bacteria. Blood 1999; 93:2395-2403.
26. Shahangian A, Chow EK, Tian X, et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest 2009; 119:1910-1920.
27. Nakamura S, Davis KM, Weiser JN. Synergistic stimulation of type I interferons during influenza virus coinfection promotes Streptococcus pneumoniae colonization in mice. J Clin Invest 2011; 121:3657-3665.
28. Smith MW, Schmidt JE, Rehg JE, Orihuela CJ, McCullers JA. Induction of pro- and anti-inammatory molecules in a mouse model of pneumococcal pneumonia after influenza. Comp Med 2007; 57:82-89.
29. Sun K, Metzger DW. Inhibition of pulmonary antibacterial defense by interferon-during recovery from influenza infection. Nat Med 2008; 14:558-564.
30. McCullers JA. Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. J Infect Dis 2004; 190:519-526.
31. McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J Infect Dis 2003; 187:1000-1009.
32. Karlström A, Boyd KL, English BK, McCullers JA. Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza. J Infect Dis 2009; 199:311-319.
33. Yamaya M, Shinya K, Hatachi Y, et al. Clarithromycin inhibits type a seasonal influenza virus infection in human airway epithelial cells. J Pharmacol Exp Ther 2010; 333:81-90.
34. Sato K, Suga M, Akaike T, et al. Therapeutic effect of erythromycin on influenza virus-induced lung injury in mice. Am J Respir Crit Care Med 1998; 157:853-857.
35. Min JY, Jang YJ. Macrolide therapy in respiratory viral infections. Mediators Inflamm 2012; 2012:649570.
36. Kitano M, Itoh Y, Kodama M, et al. Efficacy of single intravenous injection of peramivir against influenza B virus infection in ferrets and cynomolgus macaques. Antimicrob Agents Chemother 2011; 55:4961-4970.
37. Seki M, Yanagihara K, Higashiyama Y, et al. Immunokinetics in severe pneumonia due to influenza virus and bacteria coinfection in mice. Eur Respir J 2004; 24:143-149.
38. Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005; 55:i5-i21.
39. Falagas ME, Koletsui PK, Vouloumanou EK, et al. Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010; 65:1330-1346.
40. Bantia S, Arnold CS, Parker CD, Upshaw R, Chand P. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res 2006; 69:39-45.
41. Boltz DA, Ilyushina NA, Arnold CS, Babu YS, Webster RG, Govorkova EA. Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice. Antiviral Res 2008; 80:150-157.
42. Kitano M, Kodama M, Itoh Y, et al. Efficacy of repeated intravenous injection of peramivir against influenza A (H1N1) 2009 virus infection in immunosuppressed mice. Antimicrob Agents Chemother 2013; 57:2286-2294.
43. Ison MG, Hui DS, Clezy K, et al. A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults. Antivir Ther 2013; 18:651-661.
44. Nicholson KG, Aoki F Y, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355:1845-1850.
45. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283:1016-1024.
46. South East Asia Infectious Disease Clinical Research Network. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomized controlled trial. BMJ 2013; 346:f3039.
47. Lee N, Hui DS, Zuo Z, et al. A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza A and B infections. Clin Infect Dis 2013; 57:1511-1519.